Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26039937 | 0.99 | GNAI3 (0.45) | GNAI3GNAO1GNAI1PKMMEN1 | |
| SCHEMBL26040710 | 0.96 | OPRK1 (0.42) | GNAI3GNAO1GNAI1PKMMEN1 | |
| SCHEMBL25499358 | 0.88 | OPRK1 (0.38) | OPRK1ITGB3ITGA2BDPP4RAB9A | |
| SCHEMBL25499341 | 0.86 | OPRK1 (0.39) | OPRK1POLBDPP4RAB9A | |
| SCHEMBL26039093 | 0.82 | DPP4 (0.51) | GNAI3GNAO1GNAI1PKMMEN1 | |
| SCHEMBL25500916 | 0.81 | GNAI3 (0.50) | GNAI3GNAO1GNAI1PKMMEN1 | |
| SCHEMBL25502989 | 0.81 | DPP8 (0.38) | OPRK1DPP4RAB9A | |
| SCHEMBL25502988 | 0.79 | HRH2 (0.48) | GNAI3GNAO1GNAI1OPRK1 | |
| SCHEMBL25504368 | 0.78 | HRH2 (0.47) | GNAI3GNAO1GNAI1OPRK1 | |
| SCHEMBL26040010 | 0.78 | DPP7 (0.46) | GNAI3GNAO1GNAI1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159495-A1 | COMPOUND OR ITS SALT THEREOF TARGETING FIBROBLAST ACTIVATION PROTEIN, ITS PREPARATION METHODS AND ITS USES THEREOF | FIBP, FGFR2, FGFR1 | GNAI3 346/4885GNAO1 1120/4885GNAI1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.